Infection, sepsis, septic shock, biomarker, meprin-alpha
Conditions
Interventions
Group 1: Patients treated in intensive care with suspected infection, proven infection, sepsis and septic shock. Serum samples are collected from all participating patients on the day of study inclusi
Sponsors
Universitätsklinikum Schleswig-Holstein, Campus Kiel
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Treatment on an intensive care unit Written informed consent Suspected diagnosis of infection, diagnosis of infection, diagnosis of sepsis, or septic shock
Exclusion criteria
Exclusion criteria: Women during pregnancy and breastfeeding Participation in a clinical trial according to AMG (intervention study) within the last 30 days Current participation in another clinical trial (intervention study)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end point is sensitivity and specificity of serum Meprin a levels for the diagnosis of sepsis or septic shock. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are the correlation of Meprin a in serum with different patient characteristics (positivity of blood culture, Gram behavior of detected pathogens, gender differences, shock vs. no shock, and others) and the association of Meprin a to different surface protein expression patterns of regulatory monocytes and biomarkers. | — |
Countries
Germany
Contacts
Public ContactMatthias Lindner
Universitätsklinikum Schleswig-Holstein, Campus Kiel
Outcome results
None listed